Impact of the Mandibular Advancement Device on Sleep Apnea During CPAP Withdrawal
NCT: NCT05939934 · RECRUITING
Brief Summary
Obstructive sleep apnea hypopnea syndrome (OSAS) is a frequent disease with neuropsychological and cardiovascular (CV) consequences. Continuous positive pressure (CPAP), the main treatment for OSAHS, is effective on the majority of symptoms but restrictive, which can promote non-compliance. Treatment interruptions are often observed in connection with intercurrent events such as nasal obstructions or even when patients are on the move. However, randomized trials have shown that stopping treatment, even for a short time, leads to a recurrence of symptoms and significant CV disturbances (increase in blood pressure, endothelial dysfunction, cardiac repolarization disorders). It seems important to consider strategies that promote therapeutic continuity. The mandibular advancement device (MAD) is an interesting tool in this regard. MAD is as effective as CPAP on symptoms and CV data. The investigators want to assess its effectiveness as a complementary treatment during treatment discontinuation on the main consequences of OSAHS.
Frequently Asked Questions
What is Impact of the Mandibular Advancement Device on Sleep Apnea During CPAP Withdrawal?
Impact of the Mandibular Advancement Device on Sleep Apnea During CPAP Withdrawal is a clinical trial registered under NCT05939934. Current status: RECRUITING.
What is the status of NCT05939934?
The current status of NCT05939934 (Impact of the Mandibular Advancement Device on Sleep Apnea During CPAP Withdrawal) is: RECRUITING.
When did Impact of the Mandibular Advancement Device on Sleep Apnea During CPAP Withdrawal start?
Impact of the Mandibular Advancement Device on Sleep Apnea During CPAP Withdrawal started on 2024-03-05.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.